Product Information
DESCOVY 120-15 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $74.8540 per EA under NDC 61958200501. Its NADAC has been published 94 times since Dec 18, 2024.
FDA first approved this application on Apr 4, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
120; 15 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958200501
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
6/29/2026
Active Ingredients
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA208215FDA Approved
4/4/2016
TE Code
AB
On Market Since
1/7/2022
Pharmacological Classes
Price Statistics
The NADAC for DESCOVY 120-15 MG TABLET has been published 94 times since Dec 18, 2024, and over the history we have for it it has risen 5.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $74.8540 per EA |
|---|---|
| All-time high | $74.8540 (Sep 30, 2026) |
| All-time low | $71.0547 (Dec 18, 2024) |
| 52-week high | $74.8540 |
| 52-week low | $71.2426 |
| Median price | $71.2701 |
| Average price | $71.7485 |
| Largest weekly change | +4.9% (Jul 8, 2026) |
| Weeks tracked | 94 |
| Tracking since | Dec 18, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the emtricitabine and tenofovir alafenamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
emtricitabine and tenofovir alafenamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DESCOVY 120-15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DESCOVY 120-15 MG TABLET, manufactured by Gilead Sciences, Inc., is $74.8540 per EA (NDC 61958200501), effective Sep 30, 2026.
How has the price of DESCOVY 120-15 MG TABLET changed over time?
Over the history we have for it, the NADAC for DESCOVY 120-15 MG TABLET has risen 5.3%. It has been tracked across 94 weekly CMS publications since Dec 18, 2024.
What are the highest and lowest recorded NADAC prices for DESCOVY 120-15 MG TABLET?
Since Dec 18, 2024, the NADAC for DESCOVY 120-15 MG TABLET has ranged from a low of $71.0547 (Dec 18, 2024) to a high of $74.8540 (Sep 30, 2026), with a median of $71.2701 per EA.
Are there cheaper alternatives to DESCOVY 120-15 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DESCOVY 120-15 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DESCOVY 120-15 MG TABLET?
DESCOVY 120-15 MG TABLET (NDC 61958200501) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.